Skip to main content
. 2022 Aug 8;10(3):52. doi: 10.3390/diseases10030052

Figure 1.

Figure 1

Ovarian cancer cell viability after virus and/or immuno-checkpoint inhibitor treatments. (a) HUSOV4 patient sample cancer cells were treated with; media (negative control), Pembrolizumamb 20 mg/mL, TILT-123 virus (100 VP/cell), or with a combination of pembrolizumab plus TILT-123 virus. Controls were left untreated. (b) TILT-123 virus cytotoxicity in ovarian cancer cells when administrated as a monotherapy or in combination with most commonly used human PD-1 and PD-L1 antibodies. All ICI antibodies were used as 20 mg/mL. MTS assay was performed as mentioned above, with same concentrations but several different ICI. Statistics; One way ANOVA (Tukey’s multiple comparison) was used for statistics on day 7 (**** p ≤ 0.0001). Data has been gathered as triplicates and is presented as mean + SEM.